Biomarkers of Myocardial Injury in Congenital Heart Disease: More Questions than Answers

Since the first study of a biochemical marker in myocardial injury was published in Science in 1954,1 numerous circulating marker proteins have been identified as valuable biomarkers of acute myocardial injury. Currently, creatine kinase (CK)-MB mass (heart type), myoglobin, and troponin I are widely used in the diagnosis and risk stratification of myocardial ischemia in adults. Although this type of myocardial insult rarely occurs in patients with congenital heart disease (CHD), several studies have indicated that hemodynamic overload in CHD results in elevated levels of cardiac injury biomarkers, suggesting that myocardial damage also could be attributed to nonischemic etiologies.
Source: Pediatrics and Neonatology - Category: Perinatology & Neonatology Authors: Tags: Editorial Source Type: research